Fluoropyrimidine chemotherapy in a rat model: Comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols

NMR in Biomedicine

Volumn 17, Issue 3, 2004, Pages 101-131

  Lutz, Norbert W ^a,b   Naser Hijazi, Belal ^a   Koroma, Squire ^a   Berger, Martin R ^a   Hull, William E ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

5 fluorouracil; 19F NMR spectroscopy; Chemotherapy; Fluoronucleotides; Intravenous infusion; Locoregional intraarterial infusion

Indexed keywords

CATHETERS; CHEMOTHERAPY; CORRELATION METHODS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TISSUE; TOXICITY; TUMORS;

NON-TOXIC TREATMENTS; TOXICITY INDEX (TI);

BIOMEDICAL ENGINEERING;

ALPHA FLUORO BETA ALANINE; DRUG METABOLITE; FLUORINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOROURACIL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD ANALYSIS; BOLUS INJECTION; CALCULATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG TISSUE LEVEL; EX VIVO STUDY; EXPERIMENTAL DESIGN; EXPERIMENTAL MODEL; FEMALE; GROWTH RATE; KAPLAN MEIER METHOD; KIDNEY PARENCHYMA; LIVER PARENCHYMA; NONHUMAN; NONLINEAR SYSTEM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT; RAT STRAIN; REVIEW; SARCOMA; SURVIVAL TIME; TEMPERATURE; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY; FEMALE; FLUORINE; FLUOROURACIL; HUMANS; NEOPLASM TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SARCOMA; SURVIVAL RATE;

ANIMALIA;

EID: 2542418962     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/nbm.880     Document Type: Review

References (106)

1. Silen W. Hepatic resection for metastases from colorectal carcinoma is of dubious value. Arch. Surg. 1989; 124: 1021-1022.
2. Wagman LD, Kemeny MM, Leong L, Terz JJ, Hill LR, Beatty JD, Kokal WA, Riihimaki DU. A prospective randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J. Clin. Oncol. 1990; 8: 1885-1893.
3. Sasson AR, Watson JC, Sigurdson ER. Hepatic artery infusional chemotherapy for colorectal liver metastases. Cancer Treat. Res. 2001; 109: 279-298.
4. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 1999; 230: 309-318.
5. Silverberg E. Cancer Statistics. Cancer 1982; 32: 15-31.
6. Biermann HR. Intra-arterial catheterization of viscera in man. Am. J. Roentg. 1951; 66: 555-562.
7. Patt YZ, Mavligit GM. Arterial chemotherapy in the management of colorectal cancer: an overview. Semin. Oncol. 1991; 18: 478-490.
8. Blesing CH, Kerr DJ. Intra-hepatic arterial drug delivery. J. Drug Target. 1996; 3: 241-347.
9. Kemeny NE. Regional chemotherapy of colorectal cancer. Eur. J. Cancer 1995; 31A: 1271-1276.
10. Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: Is there a survival difference? Meta-analysis of the published literature. Cancer 1996; 78: 1639-1645.
11. Lorenz M, Müller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J. Clin. Oncol. 2000; 18: 243-254.
12. O'Connell MJ, Nagorney DM, Bernath AM, Schroeder G, Fitzgibbons RJ, Mailliard JA, Burch P, Bolton JS, Colon-Otero G, Krook JE. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J. Clin. Oncol. 1998; 16: 2528-2533.
13. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertino JR, Turnbull ADM, Sullivan D, Stockman J, Blumgart LH, Fong Y. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. New Engl. J. Med. 1999; 341: 2039-2048.
14. Aigner KR. Intra-arterial infusion: overview and novel approaches. Semin. Surg. Oncol. 1998; 14: 248-253.
15. Hohenberger P, Kettelhack C. Clinical management and current research in isolated limb perfusion for sarcoma and melanoma. Oncology 1998; 55: 89-102.
16. Krementz ET, Carter RD, Sutherland CM, Muchmore JH, Ryan RF, Creech O Jr. Regional chemotherapy for melanoma. Ann. Surg. 1994; 220: 520-535.
17. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 1998; 16: 301-308.
18. Meta-analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol. 1998; 16: 3537-3541.
19. Hansen RM, Quebbeman E, Anderson T. 5-Fluorouracil by protracted venous infusion. Oncology 1989; 46: 245-250.
20. Schmoll HJ, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin. Oncol. 1999; 26: 589-605.
21. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-atlantic oncology program study. J. Clin. Oncol. 1989; 7: 425-432.
22. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123-128.
23. Pizzorno G, Handschumacher RE. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem. Pharmac. 1995; 49: 559-565.
24. Mori A, Bertoglio S, Guglielmi A, Aschele C, Bolli E, Tixi L, Rosso R, Sobrero A. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother. Pharmac. 1993; 33: 179-180.
25. Hoff PM, Cassidy J, Schmoll HJ. The evolution of fluoropyrimidine therapy: from intravenous to oral. Oncologist 2001; 6(Suppl. 4): 3-11.
26. Diasio RB. An evolving role for oral fluoropyrimidine drugs. J. Clin. Oncol. 2002; 20: 894-896.
27. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7: 288-323.
28. 19F NMR studies in animal models and human urine. Drug Metab. Disp. 2002; 30: 1221-1229.
29. Mayer RJ. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. J. Clin. Oncol. 2001; 19: 4093-4096.
30. Mullen CA. Cytosine deaminase as a suicide gene in cancer gene therapy. In Gene Therapy of Cancer, Lattime EC, Gerson SL (eds). Academic Press: San Diego, CA, 1999; 201-208.
31. Heidelberger C, Danenberg PV, Moran RG. Fluorinated pyrimidines and their nucleosides. Adv. Enzymol. 1983; 54: 57-119.
32. Weckbecker G. Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmac. Ther. 1991; 50: 367-424.
33. Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmac. Ther. 1990; 48: 189-222.
34. Naguib FNM, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 1985; 45: 5405-5412.
35. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology 2001; 15(Suppl. 2): 21-26.
36. van Kuilenburg ABP, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency. Clin. Cancer Res. 2001; 7: 1149-1153.
37. Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 2002; 3: 485-492.
38. Ho DH, Townsend L, Luna MA, Bodey GP. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res. 1986; 6: 781-784.
39. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakanishi H, Nakao M, Miki T. Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma. Eur. J. Cancer 2003; 39: 541-547.
40. Guimbaud R, Guichard S, Dusseau C, Bertrand V, Aparicio T, Lochon I, Chatelut E, Couturier D, Bugat R, Chaussade S, Canal P. Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans. Cancer Chemother. Pharmac. 2000; 45: 477-482.
41. Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F, Milano G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol. 1995; 13: 1663-1670.
42. Mizutani Y, Wada H, Fukushima M, Yoshida O, Ukimura O, Kawauchi A, Miki T. The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur. J. Cancer 2001; 37: 569-575.
43. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 2000; 6: 1322-1327.
44. 19F NMR studies of fluoropyrimidine chemotherapy: a review. NMR Biomed. 1989; 2: 133-141.
45. Findlay MPN, Leach MO. In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil. Anti-Cancer Drugs 1994; 5: 260-280.
46. Martino R, Malet-Martino M, Gilard V. Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr. Drug Metab. 2000; 1: 271-303.
47. 19F-NMR resonances from the fluorouracil anabolites involved in fluoropyrimidine chemotherapy. NMR Biomed. 1999; 12: 237-248.
48. Hohenberger P, Hull WE, Schlag P. Detection of cytotoxic anabolism of 5-FU in patients with colorectal liver metastases using F-19 NMR spectroscopy following intra-operative chemotherapy. In Chirurgisches Forum 1990 für experimentelle und klinische Forschung, Häring R et al. (eds). Springer: Heidelberg, 1990; 283-287.
49. 19F-NMR spectroscopy. J. Cancer Res. Clin. Oncol. 1991; 117: 295-304.
50. Chen TB, Huzak M, Macura S, Vuk-Pavlovi S. Somatostatin analogue octreotide modulates metabolism and effects of 5-fluorouracil and 5-fluorouridine in human colon cancer spheroids. Cancer Lett. 1994; 86: 41-51.
51. 19F nuclear magnetic resonance analysis of 5-fluorouracil metabolism in four differently pigmented strains of Nectria haematococca. Appl. Environ. Microbiol. 1991; 57: 3605-3612.
52. 31P-NMR. Magn. Reson. Med. 1994; 31: 224-228.
53. 19F NMR spectroscopy. Magn. Reson. Med. 1996; 36: 445-450.
54. 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res. 1988; 48: 1680-1688.
55. 19F nuclear magnetic resonance. Clin. Chem. 1985; 31: 846-848.
56. 19F nuclear magnetic resonance spectrometry. Cancer Res. 1986; 46: 2105-2112.
57. Arellano M, Malet-Martino M, Martino R, Gires P. The anticancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br. J. Cancer 1998; 77: 79-86.
58. 19F-NMR for a patient on chronic hemodialysis. Am. J. Kidney Dis. 2002; 39: E10.
59. Sweeny DJ, Barnes S, Diasio RB. Formation of conjugates of 2-fluoro-beta-alanine and bile acids during the metabolism of 5-fluorouracil and 5-fluoro-2-deoxyuridine in the isolated perfused rat liver. Cancer Res. 1988; 48: 2010-2014.
60. 19F NMR spectrometry evidence for bile acid conjugates of alpha-fluoro-beta-alanine as the main biliary metabolites of antineoplastic fluoropyrimidines in humans. Drug Metab. Dispos. 1988; 16: 78-84.
61. McSheehy PMJ, Prior MJW, Griffiths JR. Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br. J. Cancer 1989; 60: 303-309.
62. 19F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. Cancer Res. 1991; 51: 1384-1390.
63. Kamm YJL, Peters GJ, Hull WE, Punt CJA, Heerschap A. Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. Br. J. Cancer 2003; 89: 754-762.
64. 19F nuclear magnetic resonance spectroscopy. Cancer Res. 1991; 51: 5770-5773.
65. McSheehy PMJ, Robinson SP, Ojugo ASE, Aboagye EO, Cannell MB, Leach MO, Judson IR, Griffiths JR. Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Res. 1998; 58: 1185-1194.
66. 31P magnetic resonance spectroscopy. Eur. J. Cancer 1997; 33: 2418-2427.
67. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann. Oncol. 1993; 4: 597-602.
68. 19F NMR spectroscopy. Magn. Reson. Med. 1991; 19: 113-123.
69. 19F-MRS study in vivo. Br. J. Cancer 1992; 65: 369-375.
70. 19F nuclear magnetic resonance spectroscopy study in vivo. Cancer Chemother. Pharmac. 1996; 37: 259-265.
71. 19F nuclear magnetic resonance spectroscopy. Cancer Res. 1991; 51: 5806-5812.
72. 19F magnetic resonance spectroscopy. Magn. Reson. Imag. 1992; 10: 385-392.
73. 19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine. Magn. Reson. Med. 1997; 38: 907-916.
74. Lemaire LP, McSheehy PMJ, Griffiths JR. Pre-treatment energy status of primary rat tumours as the best predictor of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo. Cancer Chemother. Pharmac. 1998; 42: 201-209.
75. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 1989; 16: 215-237.
76. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 1994; 343: 1184-1187.
77. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl Acad. Sci. USA 1990; 87: 492-496.
78. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J. Clin. Oncol. 1990; 8: 1868-1873.
79. 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed. 1998; 11: 380-387.
80. 19F-NMR studies of fluorinated drugs in humans. Adv. Drug Deliv. Rev. 2000; 41: 55-74.
81. Presant CA, Jacobson J, Wolf W, Waluch V, Weitz IC, Macdonald JS. Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. Invest. New Drugs 2002; 20: 369-376.
82. 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. Magn. Reson. Imag. 1994; 12: 497-511.
83. Schlemmer HP, Becker M, Bachert P, Dietz A, Rudat V, Vanselow B, Wollensack P, Zuna I, Knopp MV, Weidauer H, Wannenmacher M, van Kaick G. Alterations of intratumoural pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res. 1999; 59: 2363-2369.
84. Schmähl D, Rieseberg T. Resistenz eines neuen Rattenimpftumors gegen Krebs-Chemotherapeutika. Naturwissenschatten 1956; 43: 475.
85. Schmähl D, Rieseberg T. Experimentelle Untersuchungen an Ratten über die Metastasierung von Tumoren. Z. Krebsforsch. 1958; 62: 456-480.
86. Friedel P, Berger MR, Rozycki-Gerlach W, Schlag P, Schmähl D. Studies on experimental liver infusion and additional systemic detoxification. Cancer Treat. Rev. 1987; 14: 247-255.
87. Bading JR, Shahinian AH, Paff MT, Yoo PB, Hsia DW. Validation of fluorouracil metabolite analysis in excised tumor: lability of anabolites. Biochem. Pharmac. 2000; 60: 963-967.
88. 19F-NMR spectroscopy. Gene Ther. 2002; 9: 1564-1575.
89. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br. Med. J. 1990; 300: 230-235.
90. Senn S. Analysis of serial measurements in medical research. Br. Med. J. 1990; 300: 680.
91. Waynforth HB. Experimental and Surgical Technique in the Rat. Academic Press: London, 1980.
92. Creskoff AJ, Fitz-Hugh T, Farris EJ. Hematology of the rat - methods and standards. In The Rat in Laboratory Investigation, Farris EJ, Griffiths JQ (eds). Hafner: New York, 1971; 406-414.
93. Laird CW. Clinical pathology: blood chemistry. In CRC Handbook of Laboratory Animal Science, Vol. II, Melby EC, Altman NH (eds). CRC Press: Cleveland, OH, 1974; 347-436.
94. Rosner B. Fundamentals of Biostatistics, 4th edn. Duxbury Press: Boston, MA, 1995.
95. Sokal RR, Rohlf FJ. Biometry: The Principles and Proctice of Statistics in Biological Research, 2nd edn. W.H. Freeman: New York, 1981.
96. Moore DS, McCabe GP. Introduction to the Practice of Statistics, 3rd edn. W.H. Freeman: New York, 1998.
97. Martino R, Lopez A, Malet-Martino MC, Bernadou J, Armand JP. Release of fluoride ion from 5′-deoxy-5-fluorouridine, an antineoplastic fluoropyrimidine, in humans. Drug Metab. Dispos. 1985; 13: 116-118.
98. Porter DJT, Harrington JA, Almond MR, Chestnut WG, Tanoury G, Spector T. Enzymatic elimination of fluoride from α-fluoro-β -alanine. Biochem. Pharmac. 1995; 50: 1475-1484.
99. Sommadossi JP, Gewirtz DA, Cross DS, Goldman D, Cano JP, Diasio RB. Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation. Cancer Res. 1985; 45: 116-121.
100. 19F nuclear magnetic resonance. Drug Metab. Dispos. 1987; 15: 718-724.
101. Lemaire L, Malet-Martino MC, De Forni M, Martino R, Lasserre B. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br. J. Cancer 1992; 66: 119-127.
102. Fournet A, Gilard V, Malet-Martino M, Martino R, Canal P, De Forni M. Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump. Cancer Chemother. Pharmac. 2000; 46: 501-506.
103. Ren Q, Van Groeningen CJ, Hardcastle A, Aherne GW, Geoffroy F, Allegra CJ, Johnston PG, Grem JL. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells. Oncol. Res. 1997; 9: 77-88.
104. Ojugo ASE, McSheehy PMJ, Stubbs M, Alder G, Bashford CL, Maxwell RJ, Leach MO, Judson IR, Griffiths JR. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br. J. Cancer 1998; 77: 873-879.
105. Kessel D, Hall TC, Wodinsky I. Nucleotide formation as a determinant of 5-fluorouracil response in mouse leukemias. Science 1966; 154: 911-913.
106. Chu E, Lai GM, Zinn S, Allegra CJ. Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA. Mol. Pharmac. 1990; 38: 410-417.